Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
調査の概要
状態
詳細な説明
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.
Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72211
- 募集
- Arkansas Urology
-
-
California
-
Santa Barbara、California、アメリカ、93105
- 募集
- Samsun Clinic - Ridley-Tree Cancer Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- 募集
- Rocky Mountain Cancer Center
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- 募集
- Medical Oncology Hematology Consultants
-
-
Illinois
-
Hinsdale、Illinois、アメリカ、60521
- 募集
- Hope and Healing Clinical Research LLC
-
New Lenox、Illinois、アメリカ、60451
- 募集
- Hope and Healing Clinical Research LLC
-
Niles、Illinois、アメリカ、60714
- 募集
- Illinois Cancer Specialists
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46825
- 募集
- Fort Wayne Medical Oncology and Hematology
-
-
Michigan
-
Royal Oak、Michigan、アメリカ、48073
- 募集
- Comprehensive Urology
-
-
Missouri
-
Columbia、Missouri、アメリカ、65201
- 募集
- Missouri Cancer Associates
-
St Louis、Missouri、アメリカ、63110
- 募集
- Siteman Cancer Center
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- 募集
- Comprehensive Cancer Centers of Nevada - Southwest
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Fairfield、Ohio、アメリカ、45014
- 募集
- Oncology Hematology Care Clinical Trials, LLC
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401
- 募集
- Williamette Valley Cancer Institute and Research Center
-
Tigard、Oregon、アメリカ、97223
- 募集
- Compass Oncology - West
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners
-
-
Texas
-
Austin、Texas、アメリカ、78705
- 募集
- Texas Oncology
-
Tyler、Texas、アメリカ、75702
- 募集
- Texas Oncology - Northeast Texas
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- 募集
- University of Virginia Comprehensive Cancer Center
-
Norfolk、Virginia、アメリカ、23502
- 募集
- Virginia Oncology Associates
-
-
-
-
Quebec
-
Chicoutimi、Quebec、カナダ
- 募集
- Site CA01194
-
Montreal、Quebec、カナダ
- 募集
- Site CA01071
-
Montreal、Quebec、カナダ
- 募集
- Site CA01052
-
-
-
-
-
Kaohsiung City、台湾
- 募集
- Site TW01117
-
-
-
-
-
Daegu、韓国
- 募集
- Site KR01113
-
Seongnam-si、韓国
- 募集
- Site KR01063
-
Seoul、韓国
- 募集
- Site KR01065
-
Seoul、韓国
- 募集
- Site KR01084
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
- Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
- Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
- Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
- Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
- Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
- Prior pelvic radiation for any reason
- Inadequate bladder function
- Other active malignancies within 3 years prior to randomization
- Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
- Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
- Uncontrolled diabetes
- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
- Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
- Active keratitis or corneal ulcerations
- History of autoimmune disease that has required systemic treatment in the past 2 years
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days prior to randomization
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A
Enfortumab vedotin + pembrolizumab (EV + P) |
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
他の名前:
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
他の名前:
|
|
アクティブコンパレータ:Arm B
Concurrent Chemoradiotherapy (cCRT) |
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes. 55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only. 40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation. 500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
他の名前:
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
他の名前:
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Overall Survival (OS)
時間枠:Up to approximately 60 months
|
Time from randomization to death due to any cause. |
Up to approximately 60 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Investigator
時間枠:Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
時間枠:Up to approximately 60 months
|
cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology. |
Up to approximately 60 months
|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
時間枠:Up to approximately 60 months]
|
Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first. |
Up to approximately 60 months]
|
|
Time to Cystectomy
時間枠:Up to approximately 60 months
|
The time from randomization to cystectomy. |
Up to approximately 60 months
|
|
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
時間枠:Up to approximately 60 months
|
The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Cystectomy Free Survival (CFS)
時間枠:Up to approximately 60 months
|
The time from randomization to cystectomy or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Number of Participants with Treatment Emergent Adverse Event (TEAE)
時間枠:From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
|
Number of Participants with Serious TEAEs
時間枠:From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 女性の泌尿生殖器疾患と妊娠合併症
- 組織型別の新生物
- 新生物、腺および上皮
- がん
- 泌尿生殖器疾患
- 新生物
- 泌尿器疾患
- 膀胱腫瘍
- 泌尿器科の新生物
- がん、移行細胞
- 泌尿生殖器腫瘍
- 部位別新生物
- 男性の泌尿生殖器疾患
- 膀胱疾患
- 女性の泌尿生殖器疾患
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 治療
- インドール
- 無機化学物質
- 塩素化合物
- 窒素化合物
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ウラシル
- ピリミジノン
- プラチナ化合物
- 放射線療法
- キノン
- アジリン
- 用量分別、放射線
- 放射線療法の投与量
- マイトマイシン
- インドレキノン
- ゲムシタビン
- フルオロウラシル
- シスプラチン
- マイトマイシン
- ペンブロリズマブ
- Enfortumab Vedotin
- 放射線量拡散
その他の研究ID番号
- C5701009
- EV-309 (その他の識別子:Alias Study Number)
- 2026-525612-34-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。